Breaking News

Biodel, Emergent BioSolutions Enter Glucagon Mfg. Pact

By Kristin Brooks | March 6, 2014

To provide fill/finish of commercial quantities for GEM device

Biodel Inc. has signed a long-term manufacturing agreement with Cangene bioPharma Inc., doing business as Emergent BioSolutions, under which Emergent will fill and finish commercial quantities of a GEM device for use with glucagon. Financial terms were not disclosed.
Biodel’s GEM device is a customized version of Unilife's dual-chamber auto-reconstitution syringe, and is being developed for use as a rescue treatment for severe hypoglycemia. GEM is designed as an intuitive, easy-to-use device to address currently available kits that are considered difficult to assemble and operate during an emergency.
The fill/finish agreement, along with the previously-announced license and supply agreement for the GEM device with Unilife, and bulk glucagon supply agreement with Bachem, continue the company's preparation for the NDA submission anticipated in 2015 and subsequent commercial launch.
Dr. Errol De Souza, Biodel's president and chief executive officer, said, "We are pleased to reach another important milestone as we rapidly advance the commercialization of the first of our two unique glucagon rescue product candidates. We look forward to progressing through increasingly advanced stages of product development."

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important